Literature DB >> 19496019

Collapsing glomerulopathy as a complication of interferon therapy for hepatitis C infection.

Sriraj Kanungo1, Srinath Tamirisa, Rajalakshmi Gopalakrishnan, Luis Salinas-Madrigal, Bahar Bastani.   

Abstract

We present the case of a patient with chronic hepatitis C and diabetes, who rapidly progressed to end stage renal disease upon initiation of IFNalpha therapy for his HCV infection. A kidney biopsy revealed advanced collapsing glomerulopathy.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19496019     DOI： 10.1007/s11255-009-9594-1

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


  10 in total

1.  Collapsing focal segmental glomerulosclerosis with recovery of renal function: an uncommon complication of interferon therapy for hepatitis C.

Authors:  D F Stein; A Ahmed; V Sunkhara; W Khalbuss
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

2.  A woman with chronic hepatitis C infection and nephrotic syndrome who developed multiple renal lesions after interferon alfa therapy.

Authors:  Maxwell E Fisher; Michele Rossini; Edith Simmons; Raymond C Harris; Gilbert Moeckel; Roy Zent
Journal:  Am J Kidney Dis       Date:  2004-09       Impact factor: 8.860

Review 3.  Drug-induced glomerulopathies.

Authors:  Hassan Izzedine; Vincent Launay-Vacher; Edward Bourry; Isabelle Brocheriou; Svetlana Karie; Gilbert Deray
Journal:  Expert Opin Drug Saf       Date:  2006-01       Impact factor: 4.250

4.  De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection.

Authors:  Jose L Tovar; Maria Buti; Alfonso Segarra; Joaquim Majó; Rafael Esteban
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

5.  Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis.

Authors:  G D'Amico
Journal:  Kidney Int       Date:  1998-08       Impact factor: 10.612

6.  Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation.

Authors:  Brendan M McGuire; Bruce A Julian; J Steve Bynon; William J Cook; Steven J King; John J Curtis; Neil A Accortt; Devin E Eckhoff
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

7.  Focal segmental glomerulosclerosis with acute renal failure associated with alpha-interferon therapy.

Authors:  E Coroneos; G Petrusevska; F Varghese; L D Truong
Journal:  Am J Kidney Dis       Date:  1996-12       Impact factor: 8.860

8.  Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency.

Authors:  Annette Bruchfeld; Karin Lindahl; Lars Ståhle; Magnus Söderberg; Robert Schvarcz
Journal:  Nephrol Dial Transplant       Date:  2003-08       Impact factor: 5.992

Review 9.  Collapsing glomerulopathy--a new pattern of renal injury.

Authors:  Arvydas Laurinavicius; Helmut G Rennke
Journal:  Semin Diagn Pathol       Date:  2002-08       Impact factor: 3.464

Review 10.  Interferon-alpha-induced focal segmental glomerulosclerosis in chronic myelogenous leukemia: a case report and review of the literature.

Authors:  CelesteAnn T Bremer; Ashton Lastrapes; Arnold B Alper; Raja Mudad
Journal:  Am J Clin Oncol       Date:  2003-06       Impact factor: 2.339
  10 in total
  7 in total

1.  Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis.

Authors:  Glen S Markowitz; Samih H Nasr; M Barry Stokes; Vivette D D'Agati
Journal:  Clin J Am Soc Nephrol       Date:  2010-03-04       Impact factor: 8.237

Review 2.  Transplant glomerulopathy.

Authors:  Edward J Filippone; Peter A McCue; John L Farber
Journal:  Mod Pathol       Date:  2017-10-13       Impact factor: 7.842

Review 3.  De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review).

Authors:  Fabrizio Fabrizi; Alessio Aghemo; Gabriella Moroni; Patrizia Passerini; Roberta D'Ambrosio; Paul Martin; Piergiorgio Messa
Journal:  Dig Dis Sci       Date:  2013-12-08       Impact factor: 3.487

4.  A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK-1654 in healthy Japanese adults.

Authors:  Yuji Orito; Naoyuki Otani; Yuki Matsumoto; Katsukuni Fujimoto; Nobuyuki Oshima; Brian M Maas; Luzelena Caro; Antonios O Aliprantis; Kara S Cox; Osamu Tokumaru; Masaaki Kodama; Hideo Kudo; Hiromitsu Imai; Naoto Uemura
Journal:  Clin Transl Sci       Date:  2022-05-17       Impact factor: 4.438

5.  Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.

Authors:  Ming V Lin; Meghan E Sise; Martha Pavlakis; Beth M Amundsen; Donald Chute; Anna E Rutherford; Raymond T Chung; Michael P Curry; Jasmine M Hanifi; Steve Gabardi; Anil Chandraker; Eliot C Heher; Nahel Elias; Leonardo V Riella
Journal:  PLoS One       Date:  2016-07-14       Impact factor: 3.240

Review 6.  Anti-hepatitis C virus drugs and kidney.

Authors:  Paul Carrier; Marie Essig; Marilyne Debette-Gratien; Denis Sautereau; Annick Rousseau; Pierre Marquet; Jérémie Jacques; Véronique Loustaud-Ratti
Journal:  World J Hepatol       Date:  2016-11-18

7.  Multicenter Clinicopathologic Correlation of Kidney Biopsies Performed in COVID-19 Patients Presenting With Acute Kidney Injury or Proteinuria.

Authors:  Shreeram Akilesh; Cynthia C Nast; Michifumi Yamashita; Kammi Henriksen; Vivek Charu; Megan L Troxell; Neeraja Kambham; Erika Bracamonte; Donald Houghton; Naila I Ahmed; Chyi Chyi Chong; Bijin Thajudeen; Shehzad Rehman; Firas Khoury; Jonathan E Zuckerman; Jeremy Gitomer; Parthassarathy C Raguram; Shanza Mujeeb; Ulrike Schwarze; M Brendan Shannon; Iris De Castro; Charles E Alpers; Behzad Najafian; Roberto F Nicosia; Nicole K Andeen; Kelly D Smith
Journal:  Am J Kidney Dis       Date:  2020-10-10       Impact factor: 8.860
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.